Grail
Grail Stock Surges on Quest Diagnostics Integration of Galleri MCED Test
Physicians in the US can now order the blood-based multi-cancer early detection assay through Quest.
360Dx Top 30 Rockets 10 Percent in January
Of the 30 companies included, 19 companies saw their stock price increase, eight firms saw their share price decrease, and three companies remained essentially flat.
JP Morgan Healthcare Conference, Day 3: Quanterix, Grail, GeneDx
Highlights from the third day included information about Quanterix's new Simoa One platform, expected to launch at the end of 2025.
In Brief This Week: Myriad Genetics, Thermo Fisher Scientific, DeepUll, Roche, Immunovia, More
News items for the weeks of Nov. 25 and Dec. 2, 2024.
Wolfe Research Initiates Coverage of Grail With Peer Perform, Veracyte With Outperform Rating
Grail's flagship product, Galleri, detects more than 50 types of cancer, while Veracyte offers tests intended to personalize treatment for thyroid, breast, and lung cancer.
Nov 12, 2024
Grail Q3 Revenues Rise 39 Percent
Jun 24, 2024
Illumina Completes Grail Divestment
May 13, 2024
Oct 12, 2023